热景生物(688068) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 407.69 million, a decrease of 20.20% compared to the previous year[3] - Net profit attributable to shareholders was CNY -210.52 million, down 10.22% year-over-year[3] - The decline in revenue and net profit was primarily due to industry policy impacts, including price reductions and decreased demand, resulting in a revenue drop of CNY 103.21 million[5] - The operating profit and total profit decreased significantly due to asset impairment provisions and increased R&D expenditures[8] Assets and Equity - The company's total assets at the end of the reporting period were CNY 3,081.56 million, a decline of 7.35% from the previous year[4] - Shareholders' equity attributable to the parent company decreased by 19.04% to CNY 2,489.86 million[4] Impairment and Losses - The company recognized impairment losses of CNY 38.01 million on related operating assets during the reporting period[5] - The company reported an investment loss of CNY 13.51 million from joint ventures in the field of biopharmaceutical innovation[7] Research and Development - R&D investment for the newly controlled subsidiary, ShunJing Pharmaceutical, amounted to CNY 78.62 million[6] Financial Reporting - Investors are advised to note that the financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[9]